Clinical trial · Interventional
Radiotherapy With Hyperthermia in Recurrent and Radiation-Induced Sarcomas
Hyperthermia and Radiotherapy in the Treatment for In-field Recurrent and Radiation-induced Soft Tissue and Bone Sarcomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
After a screening, which consists of biopsy, physical examination, initial diffusion-weighted magnetic resonance imaging (DWI-MRI) or body computed tomography (CT) scan, blood tests and case analysis on Multidisciplinary Team (MDT) meeting, a patient with radiation-induced or in-field recurrent sarcoma will receive the hypofractionated radiotherapy with deep hyperthermia (twice a week) within three weeks. The response analysis in CT or DWI-MRI and toxicity assessment will be performed after 6 weeks. In resectable tumors, a patient will be referred to surgery. In the case of unresectability, the patient will followed-up.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radiation-Induced Cancer | Radiation-Related Malignant Neoplasm | ALIAS | 0.90 |
| Radiation Induced Neoplasms | Radiation-Related Neoplasm | ALIAS | 0.90 |
| Recurrent Sarcoma | Sarcoma | CURATED_BROADER | 0.78 |
| Recurrent Soft Tissue Sarcoma | Soft Tissue Sarcoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hyperthermia | Other | — | UNRESOLVED |
| Hypofractionated radiotherapy | Radiation | — | UNRESOLVED |
| Hypofractionated radiotherapy with boost | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Radiotherapy with hyperthermia in resectable sarcomas
- description
- 12x 3 Gy (4 fractions per week) + hyperthermia (6x) + surgery
- interventionNames
- Radiation: Hypofractionated radiotherapy
- Other: Hyperthermia
- type
- EXPERIMENTAL
- label
- Radiotherapy with hyperthermia in non-resectable sarcomas
- description
- 12x 3 Gy with simultaneous integrated boost 3.5 Gy (4 fractions per week) + hyperthermia (6x)
- interventionNames
- Other: Hyperthermia
- Radiation: Hypofractionated radiotherapy with boost
Primary outcomes (1)
- measure
- Ratio of late adverse events
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Able to provide informed consent * Eastern Cooperative Oncology Group performance status 0 - 2 * Age ≥18 years old * Histologically-proven diagnosis of radiation-induced or recurrent soft tissue sarcoma * Previous radiotherapy within the planned target volume Exclusion Criteria: * Histologic diagnosis of rhabdomyosarcoma (except spindle cell and pleomorphic subtype), osteogenic sarcoma, Ewing's sarcoma/PNET, aggressive fibromatosis * Contraindications to radiotherapy or hyperthermia * Predicted unacceptable high risk of reirradiation-related toxicity, in the Investigator's judgment * Unresectable metastases
References
Publications (5)
- BACKGROUNDde Jong MA, Oldenborg S, Bing Oei S, Griesdoorn V, Kolff MW, Koning CC, van Tienhoven G. Reirradiation and hyperthermia for radiation-associated sarcoma. Cancer. 2012 Jan 1;118(1):180-7. doi: 10.1002/cncr.26252. Epub 2011 Jun 28. PMID 21713762
- BACKGROUNDHaas RL, Miah AB, LePechoux C, DeLaney TF, Baldini EH, Alektiar K, O'Sullivan B. Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. Radiother Oncol. 2016 Apr;119(1):14-21. doi: 10.1016/j.radonc.2015.12.002. Epub 2015 Dec 21. PMID 26718153
- BACKGROUNDKosela-Paterczyk H, Szacht M, Morysinski T, Lugowska I, Dziewirski W, Falkowski S, Zdzienicki M, Pienkowski A, Szamotulska K, Switaj T, Rutkowski P. Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas. Eur J Surg Oncol. 2014 Dec;40(12):1641-7. doi: 10.1016/j.ejso.2014.05.016. Epub 2014 Sep 20. PMID 25282099
- BACKGROUNDLindner LH, Issels RD. Hyperthermia in soft tissue sarcoma. Curr Treat Options Oncol. 2011 Mar;12(1):12-20. doi: 10.1007/s11864-011-0144-6. PMID 21360087
- BACKGROUNDBorghede G, Hedelin H. Radiotherapy of localised prostate cancer. Analysis of late treatment complications. A prospective study. Radiother Oncol. 1997 May;43(2):139-46. doi: 10.1016/s0167-8140(96)01871-3. PMID 9192958